CategoryNews and events

HSCT makes the recommended list

Barts-MS rose-tinted-odometer: ★★★★★ Good news for people with MS living in the US. The National Multiple Sclerosis Society is acknowledging that autologous hematopoietic stem cell transplant (AHSCT) is an effective treatment for MS as is recommending  AHSCT a useful treatment option for pwMS who have substantial breakthrough disease activity despite treatment with high-efficacy DMTs or have...

Is the MS lexicon in need of an update?

Barts-MS rose-tinted-odometer: ★ In the last 2 days, you will have seen from my posts and the discussion that it has generated that there is a problem with the current MS lexicon. We need to get some form of nomenclature that addresses the confusion about what MS is as a disease and at what is the state and/or stage of MS for individuals with the disease. Knowing how to refer to people with MS is... diversity and youth

Barts-MS rose-tinted-odometer: ★★★★★ What do you do you do when you realise that your baby has grown up!  Several years ago someone on this blog recommended launching OCTRIMS, i.e the Online Consortium of Treatment and Research In Multiple Sclerosis. I diligently registered the domain name and approached ECTRIMS for support and they said no they weren’t prepared to support an online offering...

The forgotten many: not any more

Most of you will have heard by now that NICE has green-lighted siponimod for the treatment of active secondary progressive multiple sclerosis on the NHS. As the UK member of the EXPAND trial steering committee, Novartis who market the drug asked me for a quote, which sums up my opinion about the news. “The NICE approval of siponimod to treat secondary progressive multiple sclerosis with active...

#TeachMS: virtual MS Academy meetings

If you are a Healthcare Professional (HCP) and are interested in getting up to speed on some advanced topics around the management of MS please take a look at the programme below. We converted our November meeting to be virtual, which has opened some spaces for more people to attend. Please register via the following link: Advanced MS Academy 4-6 November 2020 Online. If you have any queries...

#MSCOVID19 & education: changing the way we manage MS one young brain at a time

Barts-MS rose-tinted-odometer: ★★★★★ At Barts-MS we spend a lot of time teaching people about MS. It is not only important to generate new information (ideas, testable hypotheses and research), but also to disseminate knowledge (teaching). However, with the COVID-19 pandemic and the resultant social distancing, almost all teaching has gone online and that does not make for very engaging and...

MSVirtual2020 #SoWhite

Last week, I sat down and watched this year’s virtual joint ECTRIMS/ACTRIMS Congress – the world’s largest annual conference dedicated to multiple sclerosis. Over three days, nearly two hundred leading MS clinicians, scientists and health care professionals appeared on the screen presenting the latest research and treatment on the disease. Most of them, I noticed, were White. Not...

MSVirtual2020: ChariotMS

Whilst COVID-19 continues to be rather all-consuming, we’ve been extremely fortunate signing all relevant contracts at the start of the pandemic enabling us to keep the momentum of ChariotMS. Recruitment was meant to start this month, however COVID-19 threw us a final dummy, and we are now on course to enrol the first participant in Jan 2021. I can hardly describe how excited I am this...

Native: Barts-MS thinks aloud

For those who missed our online journal club on radiologically isolated syndrome (RIS) or asymptomatic MS, which was held online this afternoon, you can catch-up with the banter on YouTube.

Is there any mileage in doing these live?

CoI: multiple

#ThinkSpeak: Rachel Horne

An interview with Rachel Horne who wrote the extraordinary blog post “The Kingdom of the Sick” (14th July 2020), which in my opinion is almost certainly the most well written and insightful piece on this blog.

CoI: nothing relevant in relation to this blog post



Recent Posts

Recent Comments